Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Oct 2019 to Oct 2024
Cardiac Science and GE Healthcare Expand Distribution Agreement
to Include Sale of Powerheart(R) AEDs to Hospitals in North America
GE to Market Powerheart AED G3 PRO Designed for Medical Professionals
IRVINE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cardiac Science Inc.
(NASDAQ:DFIB) announced today that it has expanded its multi-year strategic
distribution agreement with GE Healthcare, a division of General Electric
Company (NYSE:GE), under which GE will begin marketing Cardiac Science's line
of Powerheart(R)-branded automated external defibrillators (AEDs) and
fully-automatic in-hospital defibrillator-monitors (CRMs) to hospitals in the
United States and Canada.
GE's hospital sales force will begin marketing Cardiac Science's recently
FDA-cleared Powerheart AED G3 PRO, the Powerheart AED G3 and Powerheart CRM(TM)
in the first quarter of 2005. Cardiac Science will support the GE sales effort
via a group of sales specialists located in strategic North American locations.
In October, Cardiac Science made its first OEM shipments to GE of its new G3
PRO model. GE is marketing the private-labeled device under the GE-brand name
Responder(R) AED PRO in Europe, Asia, the Middle East and other international
markets.
Cardiac Science's Chairman and CEO Raymond W. Cohen said, "To date, we have had
little, if any, distribution capability in the U.S and Canadian hospital
markets. With GE as our distribution partner, we not only open up a new
important market but are also provided with immediate credibility and access.
Over the past year or so, significant demand has developed for AEDs within
hospitals. AEDs are being used to treat patients in the non-acute sections of
the hospital and are also being deployed to protect visitors and hospital
employees.
"Prospects for sales of the new G3 PRO in this market are excellent. Medical
professionals that have seen the G3 PRO simply love it," said Cohen. "They tell
us it is the perfect AED for use by physicians and nurses because it can be
easily used by either highly or minimally trained personnel given the device's
intuitive voice prompts, high resolution ECG display and capability to deliver
defibrillation shocks either semi-automatically or manually. We believe the
combination of this great new product and a powerful distribution partner will
enhance the near-term potential of the CRM and allow us to reap the benefit of
the investment we made to develop the G3 PRO."
About the Powerheart(R) AED G3 PRO
The G3 PRO is a technologically advanced AED designed for use by sophisticated
users of lifesaving equipment such as hospital personnel, medical professionals
and emergency medical technicians. The G3 PRO is unique in that it displays
the victim's heart rhythm on a built-in high resolution color electrocardiogram
(ECG) display and gives professional users the option of delivering
defibrillation shocks either semi-automatically or manually during the
emergency treatment of victims of sudden cardiac arrest. Other advanced
features include continuous cardiac monitoring capability via an ECG patient
cable, multiple rescue data storage, clear and comprehensive AED and CPR voice
prompts, infrared data transfer and optional rechargeable battery.
About the Powerheart(R) Cardiac Rhythm Module (CRM)
The CRM is a lightweight fully-featured external defibrillator that offers a
complete therapeutic monitoring package in a single device -- continuous
cardiac monitoring, synchronized cardioversion, non-invasive pacing as well as
manual, semi-automatic or fully-automatic defibrillation. Designed for use in
hospitals, the CRM can be used to monitor patients during transport, as an
emergency defibrillator or be prophylactically attached to an at-risk cardiac
patient. Once attached to the patient via its disposable electrode pads and
programmed, the CRM can operate without the need for human intervention. It
continuously monitors a patient's heart, detects the onset of life-threatening
arrhythmias and can automatically deliver defibrillation therapy to patients
suffering from Sudden Cardiac Arrest.
About Cardiac Science
Cardiac Science develops, manufactures and markets a complete line of
Powerheart(R) brand, automated public access defibrillators (AEDs), and offers
comprehensive AED/CPR training and AED program management services that
facilitate successful deployments. The company makes the Powerheart(R)
CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and
automatically treats hospitalized cardiac patients who suffer life-threatening
heart rhythms. Cardiac Science also manufactures its AED products on a private
label basis for other leading medical companies such as Nihon Kohden (Japan),
Quinton Cardiology Systems and GE Healthcare. For more information please
visit http://www.cardiacscience.com/ or call 1.949.797.3800.
This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. In addition, from time
to time the company, or its representatives, have made or may make forward
looking statements orally or in writing. The words "estimate," "potential,"
"intended," "expect," "anticipate," "believe," and similar expressions or words
are intended to identify forward looking statements. Such forward-looking
statements include, but are not limited to the achievement of future revenue
growth based on the expanded agreement with GE. Cardiac Science cautions that
these statements are subject to substantial risks and uncertainties and are
qualified by important factors that could cause actual results to differ
materially from those reflected by the forward-looking statements and should
not be relied upon by investors when making an investment decision.
Information on these and other factors is detailed in the Company's Form 10-K
for the year ending December 31, 2003, subsequent quarterly filings, and other
documents filed by the Company with the Securities and Exchange Commission.
Contact: Matt Clawson (Investors), or Raymond W. Cohen
Len Hall (Media) Chief Executive Officer
Allen & Caron Inc Cardiac Science, Inc.
949-474-4300 949-797-3800
DATASOURCE: Cardiac Science Inc.
CONTACT: Investors, Matt Clawson, , or Media, Len
Hall, , both of Allen & Caron Inc, +1-949-474-4300, for
Cardiac Science Inc.; or Raymond W. Cohen, Chief Executive Officer of Cardiac
Science, Inc., +1-949-797-3800,
Web site: http://www.cardiacscience.com/